Abstract
CpG-oligodeoxynucleotides (CpG-ODN) are potent immune stimuli being developed for use as adjuvants in different species. Toll-like receptor 9 (TLR9) is the cellular receptor for CpG-ODN in mammalian cells. The CpG-ODN with 18-24 deoxynucleotides that are in current use for human and mouse cells, however, have low activity with rabbit TLR9. Using a cell-based activation assay, we developed a type of CpG-ODN containing a GACGTT or AACGTT motif in 12 phosphorothioate-modified deoxynucleotides with potent stimulatory activity for rabbit TLR9. The developed CpG-ODN have higher activities than other developed CpG-ODN in eliciting antigen-nonspecific immune responses in rabbit splenocytes. When mixed with an NJ85 peptide derived from rabbit hemorrhagic disease virus, they had potent activities to boost an antigen-specific T cell activation and antibody production in rabbits. Compared to Freund's adjuvant, the developed CpG-ODN are capable of boosting a potent and less toxic antibody response. The results of this study suggest that both the choice of CpG-motif and its length are important factors for CpG-ODN to effectively activate rabbit TLR9 mediated immune responses.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Immunologic / chemistry
-
Adjuvants, Immunologic / pharmacology*
-
Animals
-
Antibody Formation / drug effects
-
Base Sequence
-
Cytokines / metabolism
-
HEK293 Cells
-
Hemorrhagic Disease Virus, Rabbit / metabolism
-
Humans
-
Immunoglobulin M / metabolism
-
Lymphocyte Activation / drug effects*
-
Oligodeoxyribonucleotides / chemistry
-
Oligodeoxyribonucleotides / pharmacology*
-
Peptides / chemistry
-
Peptides / pharmacology
-
Phosphates / chemistry
-
Rabbits
-
Spleen / drug effects
-
Spleen / metabolism
-
T-Lymphocytes / immunology
-
T-Lymphocytes / metabolism
-
Toll-Like Receptor 9 / metabolism*
Substances
-
Adjuvants, Immunologic
-
CPG-oligonucleotide
-
Cytokines
-
Immunoglobulin M
-
Oligodeoxyribonucleotides
-
Peptides
-
Phosphates
-
Toll-Like Receptor 9
-
phosphorodithioic acid
Grants and funding
This work was supported in part by grants from the National Health Research Institutes, Taiwan to THC (IM-102-PP-02), and from the National Science Council of Taiwan to THC (NSC102-2320-B-400-009-MY3) and LCH (NSC102-2325-B-002-06). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.